NCT01323140

Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems

An Open Label, Dose-Proportionality, Bioavailability and Dose- Titration Investigation of the Pharmacokinetics, Metabolism, Efficacy and Safety of Two Testosterone Matrix Transdermal Systems (28 cm2 and 48 cm2) in Hypogonadal Men

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Watson Pharmaceuticals · Industry
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Watson's testosterone transdermal system delivers male sex hormone through skin for the treatment of men with sex hormone insufficiency.

Detailed description

The present study is designed to characterize efficacy and safety of testosterone from the Watson's testosterone matrix transdermal system (TMTS).

Conditions

• Hypogonadism

Interventions

Type	Name	Description
DRUG	testosterone matrix transdermal system

Timeline

• Start date: 2011-04-01
• Primary completion: 2011-07-01
• Completion: 2011-07-01
• First posted: 2011-03-25
• Last updated: 2013-01-01
• Results posted: 2013-01-01

Locations

2 sites across 1 country: United States